AP-HP, Reference Center for Neuromuscular Disorders, Pitié-Salpêtrière Hospital, Paris, France.
Centre de Recherche en Myologie, Institut de Myologie, Sorbonne Université, Inserm, Paris, France.
J Neuromuscul Dis. 2021;8(4):633-645. doi: 10.3233/JND-200577.
Dominant and recessive autosomal pathogenic variants in the three major genes (COL6A1-A2-A3) encoding the extracellular matrix protein collagen VI underlie a group of myopathies ranging from early-onset severe conditions (Ullrich congenital muscular dystrophy) to milder forms maintaining independent ambulation (Bethlem myopathy). Diagnosis is based on the combination of clinical presentation, muscle MRI, muscle biopsy, analysis of collagen VI secretion, and COL6A1-A2-A3 genetic analysis, the interpretation of which can be challenging.
To refine the phenotypical spectrum associated with the frequent COL6A3 missense variant c.7447A>G (p.Lys2483Glu).
We report the clinical and molecular findings in 16 patients: 12 patients carrying this variant in compound heterozygosity with another COL6A3 variant, and four homozygous patients.
Patients carrying this variant in compound heterozygosity with a truncating COL6A3 variant exhibit a phenotype consistent with COL6-related myopathies (COL6-RM), with joint contractures, proximal weakness and skin abnormalities. All remain ambulant in adulthood and only three have mild respiratory involvement. Most show typical muscle MRI findings. In five patients, reduced collagen VI secretion was observed in skin fibroblasts cultures. All tested parents were unaffected heterozygous carriers. Conversely, two out of four homozygous patients did not present with the classical COL6-RM clinical and imaging findings. Collagen VI immunolabelling on cultured fibroblasts revealed rather normal secretion in one and reduced secretion in another. Muscle biopsy from one homozygous patient showed myofibrillar disorganization and rimmed vacuoles.
In light of our results, we postulate that the COL6A3 variant c.7447A>G may act as a modulator of the clinical phenotype. Thus, in patients with a typical COL6-RM phenotype, a second variant must be thoroughly searched for, while for patients with atypical phenotypes further investigations should be conducted to exclude alternative causes. This works expands the clinical and molecular spectrum of COLVI-related myopathies.
编码细胞外基质蛋白胶原 VI 的三个主要基因(COL6A1-A2-A3)中的显性和隐性常染色体致病性变异导致一组肌病,从早发性严重疾病(Ullrich 先天性肌营养不良症)到较轻的形式维持独立行走(Bethlem 肌病)。诊断基于临床表现、肌肉 MRI、肌肉活检、胶原 VI 分泌分析和 COL6A1-A2-A3 基因分析的组合,其解释具有挑战性。
细化与常见 COL6A3 错义变异 c.7447A>G(p.Lys2483Glu)相关的表型谱。
我们报告了 16 名患者的临床和分子发现:12 名患者在复合杂合子中携带这种变体,另一种 COL6A3 变体,以及 4 名纯合子患者。
携带这种变体在复合杂合子中与截断 COL6A3 变体的患者表现出与 COL6 相关的肌病(COL6-RM)一致的表型,伴有关节挛缩、近端无力和皮肤异常。所有患者在成年后仍能独立行走,只有三人有轻度呼吸受累。大多数患者显示出典型的肌肉 MRI 发现。在五名患者中,皮肤成纤维细胞培养中观察到胶原 VI 分泌减少。所有受检的父母均为无症状的杂合子携带者。相反,四名纯合子患者中有两名未出现典型的 COL6-RM 临床和影像学表现。培养的成纤维细胞中的胶原 VI 免疫标记显示一种细胞分泌正常,另一种细胞分泌减少。一名纯合子患者的肌肉活检显示肌原纤维排列紊乱和边缘空泡。
根据我们的结果,我们假设 COL6A3 变体 c.7447A>G 可能作为临床表型的调节剂。因此,在具有典型 COL6-RM 表型的患者中,必须彻底搜索第二种变体,而对于具有非典型表型的患者,应进行进一步的调查以排除其他原因。这项工作扩展了 COLVI 相关肌病的临床和分子谱。